Previous 10 | Next 10 |
Shares of Kodiak Sciences (NASDAQ: KOD) were skyrocketing 85.8% higher as of 10:41 a.m. EST on Monday after rising as much as 146.5% earlier in the day. This huge jump was spurred by Kodiak's announcement that it was selling a capped 4.5% royalty right on potential global net sales of experi...
Kodiak Sciences (NASDAQ: KOD ) +6.6% in pre market as the Company agrees to sell a capped 4.5% royalty right on global net sales of KSI-301 to Baker Bros. Advisors, for $225M More news on: Kodiak Sciences Inc., Healthcare stocks news, Read more ...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Evercore ISI Heal...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million . KSI-301 is Kodiak's inve...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Buying stocks just because they're going up is a great way to lose a lot of money, but that doesn't mean you should avoid every company that's signaling signs of success. These three small-cap biotech stocks have been rocketing higher all year and for good reasons. They're all heading toward th...
Kodiak Sciences, Inc. (KOD) Q3 2019 Results Conference Call November 12, 2019 05:00 PM ET Company Participants John Borgeson - Chief Financial Officer Victor Perlroth - Chief Executive Officer Jason Ehrlich - Chief Medical Officer and Chief Development Officer Conference Call ...
Image source: The Motley Fool. Kodiak Sciences Inc. (NASDAQ: KOD) Q3 2019 Earnings Call Nov 13, 2019 , 8:00 p.m. ET Operator Continue reading
Kodiak Sciences (NASDAQ: KOD ): Q3 GAAP EPS of -$0.33 in-line. More news on: Kodiak Sciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PALO ALTO, Calif. , Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the thi...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform PR Newswire Tarcocimab clinical and non-clinical data high...